mPulse Is Growing Fast and There Is Nothing to Buy

If a headline told you mPulse delivered "strong financial results" and "sustained growth" for the second quarter, the natural reflex is to wonder whether you missed a buy signal. You didn't. mPulse is a private company — there is no ticker, no SEC filing, no audited financials, and no analyst's consensus to beat. Its "Q2 results" are a corporate press release, not an earnings report. That distinction is the first thing an investor should grasp, and it changes almost everything about how to read this news.

What the release does tell us is worth understanding anyway, because it reveals a more specific — and more durable — demand driver than "AI healthcare" marketing language. That driver, and the question of whether you can ever own this growth, is the real subject.

What mPulse actually is

mPulse (formerly mPulse Mobile) is a Los Angeles-based maker of health-engagement software, what it brands "Health Experience and Insights" technology. It sits between health insurers and their members: predictive analytics to flag who needs attention, AI-driven outreach across email, text and phone, member portals, and the more boring but lucrative business of producing the regulated letters — explanations of benefits, welcome notices, prior-authorization decisions — that plans are required to send.

The scale is real. mPulse says it serves more than 450 healthcare organizations, including over 50 of the 60 largest U.S. health plans, and processes more than four billion consumer transactions a year. It is backed by growth-equity firm PSG, which put money into the company in early 2022, and it has grown partly by buying rivals including Clarity Software Solutions in 2025. In short: a well-funded, growing private business — not a stock.

Why a "connected platform" is renting a warehouse

Here is the part of the Q2 news that deserves attention. Alongside a product launch, mPulse announced in early August that it had signed a long-term lease for a new print-and-mail operating center in Phoenix, with western operations beginning in the fourth quarter. The company frames the center as adding "surge capacity" and geographic redundancy to its national delivery network, and as shortening turnaround for clients in Mountain and Pacific time zones.

That a software-and-AI company is committing to physical mail production may sound like a step backward. It isn't. It is a direct response to a rule change with a hard clock. Under the CMS Interoperability and Prior Authorization Final Rule, effective January 2026, impacted insurers must decide expedited prior-authorization requests within 72 hours and standard requests within 7 calendar days, and must give a specific reason for each denial in member-accessible form. Those are regulated, time-sensitive documents a plan cannot defer. mPulse's own reporting cites growing volume of utilization-management communications under this rule as a reason it is adding production capacity.

That is the mechanism behind "national capacity": a fast-growing, regulatory-driven, recurring flow of letters that have to go out on tighter deadlines than before. Far from being a sign of trouble, capital going into print capacity is evidence that this particular demand is real enough to warrant physical investment. It is the kind of claim a skeptical investor can actually check against announced spending rather than take on faith.

The fine print in "sustained growth"

The second thing worth noticing is what this quarter's announcement did not contain. In prior updates mPulse framed results as year-over-year revenue and profitability growth. The Q2 release, by contrast, leans on the phrase "sustained growth" without a specific revenue figure or growth percentage. That matters not because the company is in trouble — there is no evidence of that — but because it is a reminder of how you are being sold to. Private-company numbers here are not audited and are not built to Wall Street's standards; they are built to attract customers, employees and future capital. Read a string of growing qualitative adjectives as marketing, not as a financial statement.

The honest investor takeaway

None of this makes mPulse a bad business. The quality question — does the growth convert to durable cash generation — is genuinely interesting, and the regulatory tailwind is concrete. But for a retail investor the stock-quality question has a blunt answer: there is no stock. You cannot buy mPulse today, and nothing in this release changes that. The practical paths to a public stake are an initial public offering or a sale to a public acquirer, neither of which is announced or imminent.

What you can do with the information is understand what this growth signals about the insurers who buy these services — the health plans themselves are public, and this rule is putting hard deadlines on their member communications for years to come. That is a useful lens. Just don't mistake a private company's press confidence for an investment you can act on. When — and whether — mPulse ever trades publicly, this demand story will be worth revisiting. Until then, the only correct position is none at all.